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AbsTrACT
Objectives To use a data-driven approach to determine 
the existence and natural history of subtypes of 
parkinson’s disease (pD) using two large independent 
cohorts of patients newly diagnosed with this condition.
Methods 1601 and 944 patients with idiopathic 
pD, from Tracking parkinson’s and Discovery cohorts, 
respectively, were evaluated in motor, cognitive and 
non-motor domains at the baseline assessment. patients 
were recently diagnosed at entry (within 3.5 years of 
diagnosis) and were followed up every 18 months. We 
used a factor analysis followed by a k-means cluster 
analysis, while prognosis was measured using random 
slope and intercept models.
results We identified four clusters: (1) fast motor 
progression with symmetrical motor disease, poor 
olfaction, cognition and postural hypotension; (2) mild 
motor and non-motor disease with intermediate motor 
progression; (3) severe motor disease, poor psychological 
well-being and poor sleep with an intermediate motor 
progression; (4) slow motor progression with tremor-
dominant, unilateral disease. clusters were moderately to 
substantially stable across the two cohorts (kappa 0.58). 
cluster 1 had the fastest motor progression in Tracking 
parkinson’s at 3.2 (95% cI 2.8 to 3.6) UpDRs III points 
per year while cluster 4 had the slowest at 0.6 (0.1–1.1). 
In Tracking parkinson’s, cluster 2 had the largest response 
to levodopa 36.3% and cluster 4 the lowest 28.8%.
Conclusions We have found four novel clusters that 
replicated well across two independent early pD cohorts 
and were associated with levodopa response and motor 
progression rates. This has potential implications for 
better understanding disease pathophysiology and the 
relevance of patient stratification in future clinical trials.
InTrOduCTIOn
Parkinson’s disease (PD) is a progressive neurode-
generative disorder characterised by a wide range 
of motor and non-motor features, for which there 
is no known cure. However, therapeutic strategies 
might soon be available with prolonged benefits that 
could affect the underlying pathogenesis, and hence 
delay or ultimately prevent the inexorable course 
of this disease. To date, none of the 16 drugs eval-
uated for PD disease modification have succeeded 
in phase III trials, with a further eight compounds 
currently in the discovery pipeline.1 PD is an 
inherently complex disorder with known hetero-
geneity in terms of clinical presentation as well as 
rate of progression and risk of disease complica-
tions. The basis for this is only now starting to be 
understood, in terms of the role of genetic factors, 
for example, glucocerebrosidase gene mutations. 
The implications for future clinical trial design—if 
patient heterogeneity is ignored at baseline study 
selection, leading to potential confounds and misin-
terpretation of subsequent progression/complica-
tion rates—are highly significant.
Few naturalistic cohort studies in PD have been 
undertaken using large numbers of representative, 
community-ascertained patients, unselected on the 
basis of age or family history, and prospectively 
followed early from diagnosis. Such cohorts would 
more faithfully recapitulate disease evolution in 
the true-to-life populations encountered in clin-
ical practice, where disease progression reflects 
both pathophysiology and any treatment effects, as 
reported in the CamPaIGN study.2
Data-driven approaches to delineate subtypes 
using cohorts of incident PD as well as cross-sec-
tional studies3–7 have hypothesised that there are 
different PD subtypes. Better defining these subtypes 
will be important for understanding the aetiology 
of the disease, discovering biomarkers related to 
prognosis and for stratified medicine, including the 
discovery and response to new medications.8 In this 
study, we sought to better explore this aspect of PD 
using two large independent cohorts of newly diag-
nosed PD and in particular the number of distinct 
disease subtypes, their levodopa responsiveness and 
rate of motor and cognitive decline. This extends 
our previous work in this area using only one of 
the two cohorts (Discovery), without assessing 
levodopa responsiveness or the subsequent rate of 
motor and cognitive decline.9
MATerIAls And MeThOds
Patient populations
Tracking Parkinson’s is a prospective cohort of 
recently diagnosed patients with PD who were 
recruited from around the UK between February 
2012 and May 2014. Full details of this cohort and 
full inclusion/exclusion criteria have been published 
elsewhere.10 The Oxford Parkinson’s Disease 
Centre Discovery cohort (hereafter referred to as 
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Table 1 Demographic and clinical characteristics at baseline for the patients in the two studies
Variable
Tracking Parkinson’s cohort (n=1601) 
mean (sd) or n (%)
discovery cohort (n=944) mean (sd) 
or n (%) P-value difference between cohorts
Female 554 (34.6%) 334 (35.4%) 0.69*
Ethnicity (non-white) 28 (1.8%) 20 (2.1%) 0.51*
Age diagnosis (years) 65.9 (9.3) 65.9 (9.6) 0.92†
Disease duration from diagnosis (years) 1.3 (0.9) 1.2 (0.9) 0.03†
MDS-UPDRS part I‡ 9.1 (5.2) 8.8 (5.1) 0.09†
MDS-UPDRS part II‡ 9.5 (6.2) 8.7 (6.0) <0.001†
MDS-UPDRS part III‡ 22.3 (11.9) 26.4 (10.8) <0.001†
MDS-UPDRS part IV‡ 0.7 (1.7) 0.3 (1.1) <0.001†
MDS-UPDRS total (all four parts)‡ 41.8 (18.7) 44.2 (17.5) 0.002†
MoCA (adjusted for education years)‡ 25.4 (3.4) 25.0 (3.3) 0.012†
Untreated 149 (9.3%) 119 (12.6%) 0.01*
LEDD (mg) 293 (205) 282 (212) 0.20†
LEDD (those on medication) (mg) 324 (190) 327 (194) 0.77†
Hoehn and Yahr§ median (IQR) 1 (1–2) 2 (2–2) <0.001*
Motor assessments (UPDRS and Hoehn and Yahr) were rated in the clinically defined ‘on medication’ state for treated patients with PD.
*χ2 test.
†T-test.
‡Changed denominator where 80% or more of questions were answered.
§In Tracking Parkinson’s cohort, Hoehn and Yahr 1.5 and 2.5 were changed to 1 and 2, respectively, for comparison with Oxford Parkinson’s Disease Centre Discovery cohort.
LEDD, levodopa equivalent daily dose; MDS, Movement Disorders Society; MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating Scale.
Discovery) is also a prospective cohort of recently diagnosed 
patients with PD who were recruited from 11 hospitals in the 
Thames Valley region between September 2010 and January 
2016. Full details of the Discovery cohort and full inclusion/
exclusion criteria have also been published elsewhere.11 In both 
studies, patients were defined as recently diagnosed if recruited 
within 3.5 years of diagnosis. In order to exclude patients with 
similar conditions that may have been incorrectly diagnosed as 
PD, we only included individuals in both cohorts if they had 
a probability of PD ≥90% as rated by a research neurologist/
movement disorder specialist at their latest visit. Patients have 
been (and are continuing to be) followed up every 18 months. 
Both studies were funded by Parkinson’s UK.
Patient evaluation
Assessments of patients were via self-completed questionnaires 
and from outpatient clinics using standardised and validated 
scales both at baseline and follow-up. Variables used in this anal-
ysis were those adopted in our original cluster analysis paper9 and 
which were also included in the Tracking Parkinson’s cohort, and 
these included the Movement Disorders Society (MDS) revised 
Unified Parkinson’s Disease Rating Scale (UPDRS), where part 
III was measured in the ‘on’ state; Big Five Inventory; Epworth 
Sleepiness Scale; REM Sleep Behaviour Disorder Screening 
Questionnaire; Hospital Anxiety and Depression Scale; Ques-
tionnaire for Impulsive-Compulsive Disorders in Parkinson’s 
Disease; Honolulu Asia Aging Study Constipation Question-
naire; Montreal Cognitive Assessment (MoCA) adjusted for 
education years; Semantic verbal fluency (animals); Orthostatic 
blood pressure measurement; and Sniffin’ 16 odour identifica-
tion scores. The levodopa equivalent daily dose (LEDD) was 
calculated from medication use questionnaires using established 
formulae.12 In addition, a levodopa challenge was carried out 
giving us a quantitative measure of response to medication (see 
online supplementary e-appendix for more details on methods).
statistical analysis
We imputed missing data using the mean score if 80% or 
more questions were answered in any given test. Additionally, 
missing baseline data were imputed using the chained equations 
approach separately in the two cohorts. Factor analysis was used 
as a variable reduction technique on all the baseline phenotypic 
variables (details in online supplementary e-appendix). We then 
derived the clusters by using a k-means analysis of the factor 
scores and other baseline phenotypic variables not loading into 
one of the factors. Variables were standardised separately within 
each cohort to ensure that each variable had the same weighting 
within the k-means analysis. Further details are described in our 
previous publication.9
A discriminant analysis model was then fitted to the Tracking 
Parkinson’s clusters and used to predict clusters within the 
Discovery cohort. These predicted clusters were compared with 
the k-means clusters in the Discovery cohort to determine the 
stability of our approach. We used the kappa statistic to compute 
the extent of agreement and adopted accepted guidelines13 to 
determine the strength of this agreement.
We then carried out a between-cluster comparison of a range 
of clinical and demographic variables, which had not been used 
in the estimation of the clusters using analysis of variance and χ2 
tests. We modelled important disease-related variables (UPDRS 
III and MoCA scores) longitudinally using multilevel random 
slope and intercept models to estimate disease progression by 
cluster. A sensitivity analysis using pattern-mixture models was 
carried out to determine whether patients lost to follow-up may 
potentially have biased our disease progression estimates.14
resulTs
We analysed data on 1601 patients in Tracking Parkinson’s 
and 944 in Discovery (online web supplementary figure 1). 
Both cohorts had around 35% women, were predominantly 
white (>98%) and had an average age of diagnosis of about 66 
years (see table 1). The disease duration from diagnosis was on 
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Table 2 Confirmatory factor analysis within the Tracking Parkinson’s 
cohort showing standardised factor loadings of variables selected from 
exploratory factor analysis and measures of model fit
Variable
Factor 1
Psychological
well-being
Factor 2
non-tremor 
motor
MDS-UPDRS I apathy 0.512
MDS-UPDRS I fatigue 0.599
MDS-UPDRS I pain 0.544
BFI—neuroticism 0.459
HADS anxiety 0.795
HADS depression 0.863
QUIP 0.307
MDS-UPDRS III speech 0.420
MDS-UPDRS III rigidity subscore 0.535
MDS-UPDRS III bradykinesia subscore 0.769
MDS-UPDRS III postural subscore 0.609
CFI=0.909
TLI=0.932
RMSEA=0.063
CFI, TLI and RMSEA are all measures of model fit.
BFI, Big five inventory; QUIP, Questionnaire for Impulsive-Compulsive Disorders in 
Parkinson's disease.
CFI, Comparative Fit Index; HADS, Hospital Anxiety and Depression Scale; MDS, 
Movement Disorders Society; RMSEA, root mean square error of approximation; TLI, 
Tucker-Lewis Index; UPDRS, Unified Parkinson’s Disease Rating Scale.
Figure 1 Important salient clinical features of the four clusters across the two cohorts where the percentages within each cluster are from the Tracking 
parkinson’s cohort.
average 1.2–1.3 years. Compared with Tracking Parkinson’s, the 
Discovery cohort had more severe motor disease as measured by 
the UPDRS III and disease severity as measured by the Hoehn 
and Yahr or the sum score of UPDRS parts I–IV (p<0.001), and 
slightly worse average cognition as measured by the MoCA. 
However, the Tracking Parkinson’s cohort had worse motor 
aspects of experiences of daily living (UPDRS II) and motor 
complications (UPDRS IV) and had fewer untreated patients.
Cluster analysis
In our factor analysis, we found two factors: a psycholog-
ical well-being and a non-tremor motor factor (table 2), as we 
reported previously.9 This shows that within our baseline pheno-
typic variables, we had multiple variables related to psycholog-
ical well-being and to non-tremor motor function that were 
highly correlated. Using the statistics in web supplementary table 
1 helped us decide that four clusters gave us an optimal solution. 
Figure 1 highlights the important features of the clusters and 
figure 2 shows the average of each of the standardised variables 
within each cluster for the Tracking Parkinson’s and Discovery 
cohorts. The groups were arbitrarily ordered in terms of size 
for Tracking Parkinson’s, but for the Discovery cohort they 
were ordered by similarity to the Tracking Parkinson’s clusters. 
In general, the cluster patterns between the cohorts were fairly 
similar but with some differences (see below). Details of the clus-
ters are available in web supplementary table 2, which shows all 
the scores from the different tests included in the cluster analysis 
and categorised scores using standard cut-points from the litera-
ture for easier clinical interpretation. More details of the factor 
and the cluster analysis can be found in the online supplemen-
tary e-appendix.
The following describes the clusters observed in Tracking 
Parkinson’s (unless otherwise stated). The fast motor progres-
sion (1) cluster had less advanced motor features and psycho-
logical well-being but worse than average non-motor features 
such as blood pressure postural drop, olfaction and cognition 
with more symmetrical motor disease. However, within the 
Discovery cohort, the non-tremor motor was worse, rather 
than better than average, for this cluster. The mild motor 
and non-motor disease (2) cluster showed a milder form of 
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Figure 2 Within cluster means of the standardised variables for the four k-means cluster solution in both cohorts along with the 95% cI for the mean. 
positive (above the dotted line) is worse than average and negative better than average. For laterality, positive is more bilateral than average and negative 
more unilateral than average. Note that hallucinations, constipation and urinary are categorical variables and were standardised using a slightly different 
method (see online supplementary appendix 1). In Tracking parkinson’s, cluster 1 n=493 patients, cluster 2 n=459, cluster 3 n=336 and cluster 4 n=313, 
while in Discovery, cluster 1 n=218, cluster 2 n=319, cluster 3 n=196 and cluster 4 n=211. Bp, blood pressure; RBD, rapid eye movement sleep behaviour 
disorder.
the disease being better in most domains and was similar in 
the Discovery cohort analysis. The severe motor disease, poor 
psychological well-being and poor sleep (3) cluster was similar 
in the two cohorts and showed a more severe form of PD, 
especially in non-tremor motor features particularly brady-
kinesia and postural scores, worse psychological well-being 
and poor sleep and excessive daytime somnolence. The slow 
motor progression (4) cluster had severe tremor with unilat-
eral disease and was similar in Discovery except for the fact 
that the non-tremor motor features were better than average 
in Discovery and worse than average in Tracking Parkinson’s.
Web supplementary table 3 shows the agreement between 
the k-means clusters in Discovery and those predicted by the 
Tracking Parkinson’s discriminant model. This reveals an overall 
agreement of 67.9% and a kappa value of 0.58 (95% CI 0.54 to 
0.61) indicating moderate to substantial agreement.13 The major 
inconsistency comes in the mild motor and non-motor disease (2) 
cluster where 110 (34.5%) individuals are wrongly predicted to 
be in the fast motor progression (1) cluster.
Clinical and demographic correlates of the clusters
The focus for the rest of this paper is on the clusters predicted 
from the larger Tracking Parkinson’s model and applied to 
the Discovery cohort because future patients would be clas-
sified from their baseline measurements into predicted clus-
ters. We found a modest difference in disease duration since 
diagnosis (maximum average difference 3.5 months) between 
the clusters in both cohorts (table 3) but did not regard this 
as being clinically important in terms of explaining differ-
ences in phenotype. There was evidence of differences in 
gender, age at diagnosis, motor phenotype, Hoehn and Yahr 
stage, and medication use at baseline across the four clusters 
in both cohorts (p<0.001 in all variables) (see table 3). The 
mild motor and non-motor disease (2) cluster had the highest 
proportion of women and youngest age at diagnosis, while the 
fast motor progression (1) cluster had the highest age at diag-
nosis. The severe motor disease, poor psychological well-being 
and poor sleep (3) cluster had the highest proportion with the 
postural instability gait difficulty (PIGD) phenotype while the 
slow motor progression (4) cluster had the highest proportion 
of tremor-dominant disease at baseline. The LEDD at base-
line was highest in the severe motor disease, poor psycholog-
ical well-being and poor sleep (3) cluster, which also had the 
smallest proportion of untreated patients.
Within the Tracking Parkinson’s cohort, the L-dopa challenge 
was completed by 1021 (77.8%) out of 1313 patients who have 
had their 24-month visit. In the Discovery cohort, only 273 
(35.5%) out of 770 patients completed the 18-month L-dopa 
challenge indicating a lack of power and potential selection 
bias in this data set. The mean percentage decrease in UPDRS 
III comparing pre with post challenge was greater in Tracking 
Parkinson’s than in Discovery (32.1% vs 23.6%). The change 
was highest in the mild motor and non-motor disease (2) cluster 
and slightly lower than average in the slow motor progression 
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Table 4 Comparison of per-year progression rates within the two cohorts using the two approaches: multilevel random slope and intercept models 
(MLMs) versus pattern-mixture models (PMMs)
Cluster
Tracking Parkinson's cohort discovery cohort
MlM slope estimate
(95% CI)
PMM slope estimate
(95% CI)
MlM slope estimate
(95% CI)
PMM slope estimate
(95% CI)
1 3.16 (2.76 to 3.55) 3.08 (2.70 to 3.45) 2.76 (2.30 to 3.22) 2.66 (2.20 to 3.13)
MDS-UPDRS III 2 2.56 (2.18 to 2.95) 2.62 (2.23 to 3.01) 2.25 (1.63 to 2.86) 2.29 (1.72 to 2.87)
3 2.48 (1.99 to 2.97) 2.66 (2.02 to 3.31) 1.81 (1.26 to 2.37) 1.79 (1.13 to 2.46)
4 0.61 (0.11 to 1.11) 0.65 (0.09 to 1.21) 1.61 (1.08 to 2.15) 1.67 (1.04 to 2.30)
P values <0.001 <0.001 0.007 0.04
1 −0.16 (−0.26 to −0.06) −0.20 (−0.32 to −0.09) −0.19 (−0.30 to −0.07) −0.21 (−0.33 to −0.09)
MoCA adjusted 2 −0.02 (−0.12 to 0.08) −0.04 (−0.12 to 0.04) −0.10 (−0.25 to 0.05) −0.09 (−0.24 to 0.05)
3 −0.22 (−0.34 to −0.09) −0.31 (−0.50 to −0.13) −0.27 (−0.41 to −0.14) −0.34 (−0.53 to −0.14)
4 −0.04 (−0.17 to 0.08) −0.10 (−0.29 to 0.08) −0.17 (−0.30 to −0.04) −0.20 (−0.34 to −0.06)
P values 0.04 0.017 0.41 0.26
1 1.63 (1.46 to 1.81) 1.61 (1.44 to 1.78) 1.43 (1.22 to 1.64) 1.44 (1.21 to 1.67)
MDS-UPDRS II 2 1.25 (1.08 to 1.42) 1.32 (1.13 to 1.51) 1.01 (0.73 to 1.28) 0.94 (0.68 to 1.19)
3 1.51 (1.29 to 1.74) 1.68 (1.33 to 2.02) 1.25 (1.01 to 1.49) 1.41 (1.08 to 1.74)
4 1.14 (0.92 to 1.37) 1.32 (1.02 to 1.62) 1.25 (0.99 to 1.51) 1.34 (1.04 to 1.63)
P values 0.001 0.06 0.13 0.02
Cluster 1 is fast motor progression; cluster 2 is mild motor and non-motor disease; cluster 3 is severe motor disease, poor psychological well-being and poor sleep; cluster 4 is 
slow motor progression.
MDS, Movement Disorders Society; MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating Scale.
(4) cluster within both cohorts. There was strong evidence of a 
difference in response to L-dopa across the clusters in Tracking 
Parkinson’s (p=0.002), but not so strong in the smaller sample 
and potentially biased Discovery cohort (p=0.06).
Comparison of prognosis by clusters between Tracking 
Parkinson’s and discovery
In Tracking Parkinson’s, 1421 (88.8%), 1154 (72.1%) and 204 
(12.7%) have had 18-month, 36-month and 54-month assess-
ment visits, respectively, with a median follow-up time of 3.0 
years (IQR 1.8–3.2). In Discovery, 770 (81.6%), 490 (51.9%), 
230 (24.4%) and 39 (4.1%) have had 18-month, 36-month, 
54-month and 72-month assessment visits, respectively, with a 
median follow-up time of 3.0 years (IQR 1.5–4.4). All of the 
progression rates by cluster and cohort are shown in table 4. 
There was evidence of a significant difference in progression 
rates for the UPDRS III across clusters in Tracking Parkinson’s 
(p<0.001) and in Discovery (p=0.007). The same pattern of 
was seen in both cohorts. The fast motor progression (1) cluster 
had the fastest progression: 3.2 UPDRS III points per year in 
Tracking Parkinson’s and 2.8 points per year in Discovery, while 
the slow motor progression (4) cluster had the slowest motor 
progression, although the estimate for progression in the slow 
motor progression (4) cluster was markedly slower in Tracking 
Parkinson’s (0.6 UPDRS III points per year) than Discovery (1.6 
points per year) and with hardly any overlap across the 95% 
CIs (see figure 3). Repeating the analysis using the UPDRS part 
II score (web supplementary figure 2), we found the same clus-
ters in Tracking Parkinson’s with the fastest and slowest progres-
sion; however, in the Discovery cohort, we found no evidence of 
difference in progression rates.
Cognitive decline, as measured by the MoCA, was fastest in 
the severe motor disease, poor psychological well-being and poor 
sleep (3) cluster in both cohorts (figure 4), but overall there was 
no significant difference in cognitive progression rates across 
clusters (Tracking Parkinson’s p=0.04; Discovery p=0.41).
Repeating our analyses using pattern-mixture models showed 
little difference in progression rate estimates (table 4), providing 
evidence that withdrawal has not biased our estimates. Adjusting 
the slope and intercept for baseline LEDD in our UPDRS III 
models, an attempt to see the effect that treatment had on 
progression rates, we found very similar rates (results not 
included).
No significant differences in motor UPDRS III progression 
were found between conventional tremor, PIGD and mixed 
clusters (web supplementary figure 3), although in Tracking 
(p<0.001), there was some evidence to suggest that those in the 
PIGD cluster have faster cognitive decline (web supplementary 
figure 4).
dIsCussIOn 
Our analyses identified four phenotypic subgroups among 
patients recently diagnosed with PD: (1) fast motor progression 
with symmetrical motor disease, poor olfaction, cognition and 
postural hypotension; (2) mild motor and non-motor disease 
with intermediate motor progression; (3) severe motor disease 
(prominent bradykinesia/postural impairment), poor psycho-
logical well-being (mood, apathy, pain, fatigue) and poor sleep 
with intermediate motor progression; (4) slow motor progression 
with tremor-dominant, unilateral disease. The kappa statistic 
showed that the clusters calculated within the Discovery cohort 
were relatively stable compared with those predicted using the 
Tracking Parkinson’s cohort model even though some baseline 
characteristics differed significantly between the cohorts.
Our analysis has taken into account the five points recom-
mended for studies using cluster analysis.6 (1) Our sample of 
patients with PD were all recently diagnosed and hence had 
more similar disease duration than other cross-sectional studies. 
(2) We used two sample populations of patients who have been 
well phenotyped across a wide a range of important domains. 
(3) We have taken into account the limitations of k-means by (a) 
using hierarchical clustering prior to the analysis to determine 
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Figure 3 Longitudinal follow-up in MDs-UpDRs part III by cohort. Difference between clusters progression rates p<0.001 in Tracking parkinson’s and 
p=0.007 in Discovery. changed denominator where 80% or more of questions were answered. Observed data were split into yearly bins (0–1, 1–2, 2–3, 
3–4 and 4–5 years) and the means plotted. MDs, Movement Disorders society; UpDRs, Unified parkinson’s Disease Rating scale.
the number of clusters, (b) standardising all the variables so they 
have equal weighting and (c) using 500 random starts to prevent 
the selection of local optima. (4) We have looked at independent 
associations between our clusters with clinically meaningful vari-
ables such as response to L-dopa challenge and disease progres-
sion. (5) We have validated our approach using a second cohort 
collected using a nearly identical methodology.
Our previous paper reported five clusters in the Discovery 
cohort. The clusters in our new analysis are qualitatively similar 
although two of the original clusters (a) poor psychological 
well-being, rapid eye movement sleep behaviour disorder and 
sleep, and (b) severe motor and non-motor disease with poor 
psychological well-being have now merged into a single cluster 
(cluster 3). Our clusters are consistent with other similar studies 
in PD, which generally find a group with milder symptoms and 
a younger age at onset3 5 15–22 (our second cluster). Three studies 
also found a tremor-dominant group17 18 20 (our fourth cluster) 
and most studies find a group with more severe symptoms or 
rapid disease progression3 4 15–22 (our first and third clusters). 
Importantly, we have now demonstrated different rates of 
motor progression across our baseline-defined clusters, with a 
mean annual deterioration in UPDRS III scores varying signifi-
cantly from 0.6 to 3.2 points (in Tracking Parkinson’s) between 
those with slowest and fastest progression. Interestingly, we also 
found, in keeping with another study3, that poor cognition and 
postural hypotension predicted faster motor progression.
What is the clinical relevance of these findings?
Stratification, or defining different subcategories, is key to 
better understanding disease mechanisms and kinetics in PD, 
predicting disease course and ultimately delivering personalised 
management strategies. The emerging focus of PD trial design 
is on early motor disease, including novel immunomodulatory 
therapies that require intensive and invasive monitoring. Tradi-
tionally, little account has been taken of disease heterogeneity 
in early PD when selecting patients for randomised, place-
bo-controlled studies. However, our results show that baseline 
phenotype is associated with variable rates of subsequent motor 
progression, although confounded by potential medication 
response effects. The mean difference in UPDRS motor scores 
between the fastest and slowest motor progression subtypes in 
Tracking Parkinson’s was 2.6 points, equivalent to the primary 
hierarchical endpoint of several studies, including the ADAGIO 
study.23 Recruitment without taking into account heterogeneity 
and potential sources of recruitment bias may lead to less effi-
cient designs, though there are various trade-offs between the 
cost of selecting patient subgroups, the sample size required for 
demonstrating a reduction in disease progression and increasing 
the length of follow-up.
strengths and limitations
This study has used two of the largest PD incidence cohorts 
worldwide. In addition, the methods were designed collab-
oratively with similar variables being collected using almost 
identical inclusion criteria, though the source of recruitment 
differed. While this may impact on the frequency of the subtypes 
of PD, it should not influence the consistency of the clusters 
or the within-cluster progression rates. It is possible that some 
patients will turn out to have other parkinsonian disorders, such 
as multiple system atrophy, despite only including those with a 
diagnostic probability of ≥90% at the latest visit, especially in 
the fast progression cluster. We had little missing data and we 
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Figure 4 Longitudinal follow-up in Montreal cognitive assessment (Moca) by cohort. Difference between cluster progression rates p=0.04 in Tracking 
parkinson’s and p=0.41 in Discovery. changed denominator where 80% or more of questions were answered. Observed data were split into yearly bins 
(0–1, 1–2, 2–3, 3–4 and 4–5 years) and the means plotted.
used imputation methods to reduce any bias. The association 
we found with levodopa response (which was analysed as rela-
tive change) may simply reflect the fact that the second cluster 
has milder disease, and since our estimates of motor function is 
carried out in the ‘on’ state, we would expect those with mild 
motor disease to be those who respond well to the medication. 
We are also limited by the proportion who completed the L-dopa 
challenge although the vast majority of those missing this data in 
the Tracking Parkinson’s cohort is due to them either not taking 
levodopa as part of their normal medication regime or not 
reaching the 24-month time point. Levodopa response is also 
composed of both short-duration and long-duration responses.24 
Our levodopa challenge only measures the short-term response 
and our pre-dose scores are largely determined by the long-dura-
tion response. Also, the long-duration response is typically much 
larger than the short-duration response.
We used non-statistical criteria to help judge the best 
number of clusters, as the optimal number of clusters can differ 
depending on which statistic is the primary focus. Each cohort 
has its strengths and weaknesses. Tracking Parkinson’s is larger 
with more centres from a wider area of the UK population. The 
Discovery cohort used fewer clinicians to assess participants and 
had lower inter-rater variability. Discovery had more disabling 
disease and slightly worse cognitive function at baseline. Each 
cohort may have a slightly different mix of patients, but this will 
also occur in patients recruited for different clinical trials.
The major limitation in this analysis is that most of our data are 
restricted to the first 3 years of follow-up due to the studies being 
ongoing and patients not yet reaching 4.5 years of follow-up. We 
suspect this has reduced our power to detect differences between 
the clusters. The associations we saw between clusters and 
progression rates could be due to non-linearity of growth rates; 
however, non-linearity cannot be tested until the vast majority of 
patients have four or more observations.
We took a pragmatic perspective where disease progres-
sion estimates reflected both pathophysiology and treat-
ment effects. An alternative approach is measurement of the 
untreated (underlying) progression of subtypes, which reduces 
potential confounding effects of dopaminergic therapy in 
modifying disease progression, and has been applied else-
where.25 26 Accordingly the generalisability of our method may 
be limited if different treatment regimes were used in other 
clinical settings.
Neuropathological characterisation of the patient clusters at 
post mortem would help to address the question of the distri-
bution and loads of α-synuclein, tau, vascular and amyloid 
pathology in driving both baseline clinical phenotype and subse-
quent motor and cognitive progression throughout the disease 
evolution of PD.27 It is intriguing to speculate whether patients 
in cluster 1, who have the fastest motor progression, prominent 
baseline non-motor symptoms, more symmetrical disease and 
a poor levodopa response, are defined by prominent cerebro-
vascular or amyloid pathologies. Clear delineation of patient 
subtypes is likely to introduce other potential therapeutic targets 
and lifestyle interventions to the clinical trials arena that look 
beyond pure α-synuclein-driven pathology. To date, a total of 
345 subjects with PD (195 Tracking Parkinson’s, 150 Discovery 
cohort) have signed up to the nationally funded Parkinson’s UK 
Brain Donation programme, with six brains now available for 
neuropathological characterisation to begin to address these 
issues.
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COnClusIOn
We have found four clusters that replicate across two large inde-
pendent cohorts of newly diagnosed patients with PD and which 
are associated with different responses to levodopa and motor 
progression rates. Future work should examine the reasons for 
these differences, and with longer follow-up and using growth 
mixture models, we should be able to identify more easily patient 
groups with different progression rates and how this relates to 
their baseline characteristics. This will also allow us to determine 
the robustness and clinical use of stratifying patients early in the 
disease course with better defined endpoints.
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